Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma

Masaaki Takai1, Takatoshi Nakagawa2, Akiko Tanabe1, Yoshito Terai1, Masahide Ohmichi1, and Michio Asahi2,*

1Department of Obstetrics and Gynecology; Faculty of Medicine; Osaka Medical College, Osaka, Japan; 2Department of Pharmacology, Faculty of Medicine; Osaka Medical College, Osaka, Japan

Keywords: HIF-1, mTOR, MEK inhibitor, ovarian clear cell carcinoma, PI3K pathway, PP2A, Ras pathway

Abbreviations: ERK, extracellular signal-regulated kinase; 4E-BP, eukaryotic initiation factor 4E-binding-protein; HIF-1, hypoxia-inducible factor-1; MEK, mitogen-activated kinase/extracellular signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; mTOR, mammalian target of rapamycin; pVHL, von Hippel–Lindau protein; OCCC, ovarian clear cell carcinoma; OE, ovarian endometrioid carcinoma; OM, ovarian mucinous carcinoma; OS, ovarian serous carcinoma; RCC, renal cell carcinoma; RCCC, renal clear cell carcinoma; S6K, p70 ribosomal S6 kinase; PP2A, protein phosphatase 2A.

Hypoxia-inducible factor-1 (HIF-1) is one of the most promising pharmacological targets for all types of cancer, including ovarian cancer. Ovarian clear cell carcinoma (OCCC) has poor prognosis because of its insensitivity to chemotherapy. To elucidate the characteristics of this troublesome cancer, we examined HIF-1α expression under normoxia or hypoxia in various ovarian cancer cell lines. HIF-1α was highly expressed under normoxia only in RMG-1, an OCCC cell line. To examine whether HIF-1 is involved in the tumorigenesis of RMG-1 cells, we established HIF-1α-silenced cells, RMG-1HKD. The proliferation rate of RMG-1HKD cells was faster than that of RMG-1 cells. Furthermore, the activity of MEK/ERK in the Ras pathway increased in RMG-1HKD cells, whereas that of mTOR in the PI3K pathway did not change. Activation of the Ras pathway was attributable to the increase in phosphorylated MEK via PP2A inactivation. To confirm the crosstalk between the PI3K and Ras pathways in vivo, RMG-1 or RMG-1HKD cells were transplanted into the skin of nude mice with rapamycin (an inhibitor of mTOR), PD98059 (an inhibitor of MEK), or both. RMG-1HKD cells showed higher sensitivity to PD98059 than that observed in RMD-1 cells, whereas the combination therapy resulted in synergistic inhibition of both cells. These findings suggest that inhibition of HIF-1, a downstream target of mTOR in the PI3K pathway, activates the Ras pathway on account of the increase in MEK phosphorylation via PP2A inactivation, and the crosstalk between the 2 pathways could be applied in the combination therapy for HIF-1-overexpressing cancers such as OCCC.

Introduction

Ovarian cancer is the fourth most common cause of cancer death among women in the United States, with more than 22,240 new cases diagnosed and 14,030 deaths estimated to have occurred in 2013.1 Ovarian cancer is divided into biologically distinct histological subtypes: ovarian serous carcinoma (OS), ovarian endometrioid carcinoma (OE), ovarian mucinous carcinoma (OM), and ovarian clear cell carcinoma (OCCC). Among these 4 subtypes, OCCC is relatively resistant to standard chemotherapy, a combination of paclitaxel and platinum based drugs, resulting in poorer prognosis than the other subtypes.2 Therefore, there is an urgent need to develop a novel therapy for OCCC.

Molecular target drugs have been developed against cancer. The PI3K/Akt/mTOR pathway (PI3K pathway) and the Ras/Raf/MEK/Erk1/2 pathway (Ras pathway) are 2 of the most common dysregulated kinase cascades in human cancer and are considered as potential drug targets.3 In ovarian cancer, the aberrant activation of the PI-3 kinase pathway was associated with a poor prognosis.4

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase and a component of mTORC1 and mTORC2, which have been shown to be involved in the onset and progression of diabetes, cancer, and aging5 via the downstream targets including hypoxia-inducible factor-1 (HIF-1).6,7 HIF-1, which is composed of 2 subunits, α and β, activates the transcription of various genes that code for proteins involved
in angiogenesis, glucose metabolism, and cell proliferation. An increased activity in solid tumors has been reported previously. The β subunit is constitutively expressed, whereas the α subunit is regulated by the concentration of oxygen in a ubiquitin-dependent manner via the E3 ligase pVHL, which is a von Hippel–Lindau tumor suppressor. Genetic and epigenetic alterations in the VHL gene have been detected in most sporadic renal cell carcinomas, including renal clear cell carcinoma (RCCC). The role of VHL mutations in the etiology of RCCC remains elusive. HIF-1α expression is regulated not only by its degradation but also by its synthesis. It has been earlier proposed that HIF-1α synthesis in RCCC is mainly regulated by activation of the PI3K pathway. Although it is not the case of RCCC, we have previously reported that the activation of the PI3K pathway via cisplatin, a platinum-based anti-cancer drug, in cisplatin-resistant ovarian cancers resulted in overexpression and nuclear accumulation of HIF-1α.

Rapamycin analogs, mTOR inhibitors, such as orally administered everolimus and intravenously administered temsirolimus have been used in the treatment of advanced renal cell carcinomas and are currently considered as a potential therapeutic regimen for RCCC. The biggest problem of molecular target drugs is the occurrence of resistance. Inhibition of mTOR paradoxically activates the phosphorylation of Akt and eIF4, and the PI3K and Ras pathways are known to interact with each other. It has been reported that biopsy-accessible solid tumors of advanced disease treated with everolimus have a higher level of activation of the ERK pathway that follows in an administration schedule-dependent manner. However, the mechanisms by which the 2 pathways regulate each other remain unclear.

To gain insight into the effect of HIF-1 inhibition on tumor progression, we evaluated the effect of HIF-1α on cell or tumor growth in vitro and in vivo using the HIF-1α-silenced human RCCC cell line, RMG-1. We also investigated the mechanisms by which the PI3K and Ras pathways interact and regulate each other. Furthermore, we assessed the utility of a combination therapy using molecular target drugs in the treatment of HIF-1-overexpressing cancers such as RCCC.

Results

High expression level of HIF-1α in the human RCCC cell line RMG-1 under normoxia

mTOR is considered a therapeutic target for various cancers such as renal cell carcinoma and RCCC. On the other hand, HIF-1α is known to be involved in the progression of various cancers, including ovarian cancer, and is highly expressed in certain types of cancers. Using 5 human ovarian cancer cell lines, A2780, A2780CP (a cisplatin-resistant clone of A2780), CaOV3, SKOV3, and RMG-1, we examined the expression of HIF-1α under normoxia or hypoxia, because this protein has been reported as stable during hypoxia. The RMG-1 cell line is an RCCC, whereas the others are OSs. As expected, HIF-1α expression was upregulated in all 5 cell lines under hypoxia compared with that under normoxia (Figs. 1A and B). However, HIF-1α expression under normoxia varied among the 5 cell lines. The expression level of HIF-1α in RMG-1 cells, the only RCCC cell line among the 5 cell lines, under normoxia was significantly higher than that in the other 4 OS cell lines.

mTOR inhibition by rapamycin suppressed the expression level of HIF-1α in RMG-1 cells

To elucidate the role of mTOR in HIF-1α expression in the RCCC cell line RMG-1 during normoxia, we treated intact RMG-1 cells with rapamycin (an inhibitor of mTOR) for 24 h and examined the expression of HIF-1α using real-time PCR analysis. At the same time, we also evaluated the expression of HIF-1α in RMG-1RR cells, a rapamycin-insensitive RMG-1 clone. HIF-1α expression was significantly suppressed in RMG-1 cells after rapamycin treatment for 24 h (Fig. 2A). Conversely, the expression of HIF-1α in RMG-RR cells was lower at baseline than that in intact RMG-1 cells and did not change following treatment with rapamycin (Fig. 2A).

RMG-1KHD cells showed a higher proliferation rate than intact RMG-1 cells

The observed HIF-1α suppression by rapamycin suggested that the expression of HIF-1α in intact RMG-1 cells under normoxia was upregulated by mTOR. To gain insights into the role of HIF-1 in RCCC, we prepared HIF-1α-silenced RMG-1 (RMG-1KHD) cells. The expression of HIF-1α in RMG-1KHD cells was significantly lower than that observed in intact RMG-1 cells (approximately 10% of that observed in intact RMG-1 cells) (Fig. 2B). The proliferation rate of intact RMG-1 and RMG-1KHD cells was also investigated. RMG-1KHD cells grew faster than intact RMG-1 cells in both anchorage-dependent (Fig. 2C) and -independent assays (Figs. 2D and E), suggesting that HIF-1α may play a role not only in mTOR-mediated cancer progression but also in the reciprocal activation of other pathways. A greater size and number of colonies were observed in RMG-KHD cells than in intact RMG-1 cells (Fig. 2E).

Decreased PP2A activity induced an increase in the rate of MEK phosphorylation in RMG-1KHD cells

Next, we examined the phosphorylation status of 2 major signaling pathways, the PI3K and Ras pathways, in RMG-1 treated with or without rapamycin for 24 h, RMG-1RR, and RMG-1KHD cells. Rapamycin clearly suppressed the phosphorylation of S6K, a downstream target of mTOR, as well as HIF-1 separately. The phosphorylation status of Akt, an upstream kinase of mTOR, in RMG-1 cells was similar to that observed in RMG-1RR or RMG-1KHD cells and did not change after the addition of rapamycin (Fig. 3A). Based on the phosphorylation status of the Ras pathway, we inferred that the phosphorylation rate of MEK was higher in RMG-1KHD cells (Fig. 3B). Because the phosphorylations of Raf-1 and B-Raf, upstream kinases of MEK, did not change in RMG-1KHD cells as well as RMG-1 cells treated with rapamycin for 24 h or RMG-1RR cells compared to RMG-1
cells (Fig. 3B), we hypothesized that the change in the phosphorylation status of RMG-1HKD cells may be due to its phosphatase activity. Because protein phosphatase 2A (PP2A) has been shown to play a role in MEK regulation, we examined both the expression and activity of PP2A in RMG-1HKD cells. The expression level of PP2A in RMG-1HKD cells was almost comparable to that observed in RMG-1 cells (Fig. 4A). In contrast, PP2A activity in RMG-1HKD cells significantly decreased compared with that observed in RMG-1 cells (almost half of the activity) (Fig. 4B). These findings suggest that inactivation of PP2A was responsible for the elevated MEK phosphorylation in RMG-1HKD cells.

**HIF-1 modulated the proliferation of RMG-1 cells through regulation of the Ras pathway via PP2A.**

To investigate whether PP2A regulates MEK activity in RMG-1 cells, we exploited cantharidin, a potent and specific inhibitor of PP2A. The RMG-1 cells were cultured at various concentrations (0, 0.1, 1, 10 nM) of cantharidin, and the proliferation rate was examined with a WST-8 reagent. One or 10 nM of cantharidin significantly increased the proliferation rate of RMG-1 cells at 24 h after the treatment, although it was lower than that of RMG-1HKD cells (Fig. 4C, Table 1). The effect of 10 nM cantharidin lasted until 72 h after the treatment (Fig. 4C, Table 1). The phosphorylations of MEK and ERK after the cantharidin treatment were also evaluated by Western blot and densitometric analyses. As expected, the amount of phosphorylated -MEK (p-MEK) and –ERK (p-ERK) were elevated in a dose-dependent manner (Fig. 4D). Collectively, these results strongly suggest that the suppression of HIF-1α upregulated the proliferation of RMG-1 cells through activation of the Ras pathway via PP2A inhibition.

**Simultaneous inhibition of PI3K and Ras pathways strongly inhibited the proliferation of intact RMG-1 and RMG-1HKD cells.**

Next, we evaluated the effects of mTOR, MEK inhibitor, or both on the proliferation rate of intact RMG-1 or RMG-1HKD cells. A significant decrease in the proliferation rate of RMG-1 cells was observed using the mTOR inhibitor rapamycin (25 nM) or the MEK inhibitor PD98059 (10 μM), whereas their combination resulted in synergistic inhibition of RMG-1 cell proliferation (Fig. 5A, Table 2). The inhibitory effect of each agent or combination of agents on the proliferation of intact RMG-1 cells was evident as early as 24 h after treatment and continued until 72 h. Although the proliferation rate of RMG-1HKD cells was also inhibited in each treatment (Fig. 5B, Table 3), the inhibitory pattern of each inhibitor differed from that observed in intact RMG-1 cells. Consistent with the finding presented in Fig. 2C, the proliferation rate of RMG-1HKD cells was higher than that of intact RMG-1 cells at baseline without the inhibitors, and the proliferation rate of both cell lines was similarly inhibited by rapamycin. On the other hand, inhibition of proliferation by PD98059 in RMG-1HKD cells was more efficient than that in intact RMG-1 cells (Figs. 5A and B, Tables 1 and 2). The elevated phosphorylation of MEK/ERK in RMG-
HKD cells may be responsible for the higher sensitivity to PD98059 than that observed in intact RMG-1 cells. The combination of the 2 inhibitors compromised the proliferation of intact RMG-1 and RMG-1HKD cells (Figs. 5A and B, Tables 2 and 3).

Simultaneous inhibition of PI3K and Ras pathways strongly inhibited the proliferation of intact RMG-1 or RMG-1HKD cells in vivo. Figs. 5A and B show that the combination of rapamycin and PD98059 strongly inhibited the proliferation of both intact RMG-1 and RMG-1HKD cells in vitro. To confirm whether this observation also occurs in vivo, a subcutaneous transplant mouse model was used in the next experiment. Either intact RMG-1 or RMG-1HKD cells were subcutaneously implanted into the backs of nude mice (Balb/c nu/nu). Once the tumor reached 50 mm³ in volume, rapamycin, PD98059, or both were injected intraperitoneally every 3 d for 4 weeks. The tumor volume was recorded every week. After 4 weeks, the tumor volume generated by intact RMG-1 cells in the absence of inhibitors reached approximately 300 mm³ (Fig. 5C). Although the injection of either rapamycin or PD98059 also inhibited tumor growth, a combination of the 2 inhibitors suppressed tumor growth more efficiently (Figs. 5C and 6A and B, Table 4), consistent with our in vitro data (Fig. 5A). The same result

Figure 2. Comparison of RMG-1, RMG-1RR, and RMG-1HKD cells. (A) HIF-1α expression in RMG-1 and RMG-1RR cells. HIF-1α expression was measured by real-time PCR. RMG-1 and RMG-1RR cells were plated overnight, exposed to 100 nM of rapamycin for 24 h, and then subjected to real-time PCR using the extracted RNAs. HIF-1α expression in RMG-1 cells was calculated to be 1. (B) HIF-1α expression in RMG-1 and RMG-1HKD cells. HIF-1α expression in RMG-1 and RMG-1HKD cells was analyzed by real-time PCR as described in (A). (C) The proliferation rate of RMG-1 and RMG-1HKD cells was examined using a cell counting kit-8 (Wako Pure Chemical Industries, Osaka, Japan). (D) Colony formation assay of RMG-1 and RMG-1HKD cells. For the colony formation assay, a 2-layer method was used. The number of colonies was manually counted at 4 weeks after colony formation. The experiments were performed in replicates. The colony numbers are presented as a bar graph. (E) Representative images of RMG-1- and RMG-1HKD-derived colonies. The areas marked by squares are magnified and designated at the bottom. All statistics analyses were performed using JMP software (SAS Institute Inc.). (**: P < 0.01).
was observed in RMG-1HKD cell-implanted mice (Figs. 5D and 6A and C, Table 5), except that PD98059 was more effective in RMG-1HKD cells than in RMG-1 cells (Figs. 5C, D and 6), which is also consistent with our in vitro findings (Figs. 5A and B). The observation that PD98059 was more effective in RMG-1HKD cells appears quite reasonable because MEK activity was higher in RMG-1HKD cells than in intact RMG-1 cells (Fig. 3B).

**Discussion**

The PI3K and Ras pathways are the major signaling pathways for cell proliferation and survival. Abnormalities involving these pathways have been reported in various cancers. Higher PI3K activity has been reported in 40% of ovarian cancer patients, implicating that PI3K may be a major oncogenic gene in ovarian cancer. Although prognoses vary among tissue types, OCCC has been strongly associated with poor patient outcomes. Mutations in PIK3CA, which encodes for the catalytic subunit of PI3K, has been reported in 20%–30% of OCCC patients. Following the approval of the application of VEGF inhibitor, bevacizumab, in ovarian cancer, clinical tests for combination therapies using conventional drugs and a single therapy of an mTOR inhibitor, temsirolimus, are currently in progress. mTOR inhibitors are expected to be effective, particularly for PIK3CA OCCC, which features an upregulated PI3K pathway.

To gain insight into the overall effects of mTOR inhibitors on OCCC, we evaluated the effect of rapamycin on the gene expression of signaling molecules in RMG-1 cells. We focused on HIF-1α, a downstream target of mTOR. This molecule is involved in cancer progression not only in hypoxic conditions as a pivotal molecule in the Warburg effect but also in normoxic conditions. The PI3K pathway plays an important role, particularly in normoxic conditions.

Rapamycin treatment of RMG-1 cells for 24 h in normoxic conditions resulted in downregulation of HIF-1α, suggesting a suppressed PI3K pathway (Fig. 2A). A pVHL-dependent pathway regulated the degradation of HIF-1α. RCCC is associated with the tumor suppressor gene VHL, which is inactivated in 90% of sporadic tumors. Because VHL mutations have not been well studied in ovarian cancer, we screened for VHL mutations in RMG-1 cells.
No VHL mutation was detected within the open reading frame of RMG-1 cells (data not shown), indicating that the high expression of HIF-1α may be a result of protein synthesis, not degradation. In terms of protein synthesis, the observed upregulation of HIF-1α may be due to the activation of eIF4E via the phosphorylation of 4E-BP, which is a downstream target of mTOR. Thus, the PI3K pathway may be closely involved in the upregulation of HIF-1α in normoxic conditions.

HIF-1α was suppressed in RMG-1RR as well as in RMG-1 cells after rapamycin treatment (Fig. 2A). MEK/ERK was activated in both cell lines, whereas mTOR/S6K was inactivated (Fig. 3), implicating that the transient or persistent suppression of mTOR induced activation of the Ras pathway, which may inhibit the PI3K pathway, including mTOR, HIF-1, and S6K.12 Although it has been reported that S6K plays a pivotal role in the feedback mechanism of the PI3K pathway,27 HIF-1, another downstream of mTOR, may play a role in the crosstalk between the PI3K and Ras pathways,12 not in the feedback mechanism. This hypothesis was further supported by the data shown in Figs. 2C, D, and E.

Because the HIF-1 mechanism for crosstalk between the PI3K and Ras pathways remains unknown, we first examined the phosphorylation of signaling molecules of both pathways in RMG-1 and RMG-1HKD cells. The results showed that the phosphorylation of MEK and the downstream ERK, which is a downstream target of mTOR, was augmented in RMG-1HKD cells compared with that observed in RMG-1 cells (Fig. 3B). The phosphorylations of B-Raf and Raf-1, upstream kinases of MEK/ERK in the Ras pathway, did not change in RMG-1HKD cells (Fig. 3B), indicating that HIF-1α suppresses MEK and the downstream ERK. We next examined PP2A, one of the major serine/threonine phosphatases involved in the regulation of the Ras pathway. The regulatory effects of PP2A on the Ras pathway vary among cells and tissues.18 A previous study showed that MEK was hyperphosphorylated, whereas PP2A was downregulated upon ERK silencing by siRNA in human lung fibroblasts.18 In neuronal PC12, rat

---

**Figure 4.** Expression level and activity of PP2A in RMG-1 and RMG-1HKD cells. (A) The expression level of PP2Ac, a catalytic subunit of PP2A. The expression of PP2Ac was examined by Western blot analyses using an anti-PP2Ac Ab in RMG-1 and RMG-1HKD cells. The bands were densitometrically analyzed using Quantity One software (Bio-Rad, Hercules, CA). (B) PP2A activity in RMG-1 and RMG-1HKD cells was measured with a PP2A immunoprecipitation phosphatase assay kit (Millipore, Billerica, MA). (C) The proliferation rate of RMG-1 cells in the presence of cantharidin (0, 0.1, 1, 10 nM) was examined using a cell counting kit-8 (Wako Pure Chemical Industries, Osaka, Japan). (D) Phosphorylations of MEK and ERK were measured in RMG-1 cells in the presence of cantharidin (0, 0.1, 1, 10 nM), a PP2A inhibitor. The phosphorylation and total expression levels of the kinases were examined by Western blot analyses. The bands were also densitometrically analyzed using Quantity One software (Bio-Rad, Hercules, CA). Statistical analyses were performed using JMP software (SAS Institute Inc.). (n = 3 for both (A) and (D), *: P < 0.05, **: P < 0.01).
phaeochromocytoma cells, PP2A could also dephosphorylate Raf-1 kinase or ERK. Neither Raf-1 or B-Raf may be the substrate for PP2A in RMG-1 cells, because we couldn’t detect any changes in the phosphorylation status of Raf-1 as well as that of B-Raf in RMG-1HKD cells, in which PP2A was suppressed, in comparison with RMG-1 cells (Figs. 3B and 4A and B). The expression level of PP2Ac, a catalytic subunit of PP2A, in RMG-1HKD cells, did not change compared with that observed in RMG-1 cells, whereas its activity significantly decreased (Figs. 4A and B), implicating that HIF-1 inhibition may regulate the Ras pathway by MEK activation via PP2A inactivation. To confirm the speculation, RMG-1 cells were treated with cantharidin, a specific inhibitor of PP2A. The result revealed that the treatment resulted in higher phosphorylations of MEK and ERK and cell proliferation rate in RMG-1 cells in a dose dependent manner (Figs. 4C and D). The mechanism behind the regulation of PP2A via HIF-1 remains to be established. Our research team is currently investigating this issue.

Although mTOR inhibitors are a promising drug for various tumors, the biggest and inevitable concern associated with this reagent is drug resistance. In a previous study, sensitivity to rapamycin varied among different cancer cell lines by 3 orders of function. Inhibition of mTOR paradoxically activates the phosphorylation of Akt and eIF4E, and the PI3K and Ras pathways are known to interact with each other. A feedback loop in the PI3K pathway where an mTOR inhibitor may activate Akt probably via S6K has been described previously. Figure 3A shows that an increase in Akt phosphorylation in RMG-1HKD cells was not detected, suggesting that mTOR inhibition may induce reciprocal activation of other pathways such as the Ras pathway. Consistent with this notion, we found that MEK and ERK in the Ras pathway were activated in RMG-1HKD cells (Fig. 3B), whereas Akt was not (Fig. 3A). HIF-1α may not play a role in this feedback regulation and instead may directly downregulate MEK phosphorylation via PP2A (Fig. 3B).

While the growth of RMG-1 and RMG-1HKD cells was slightly suppressed by either rapamycin or PD98059, a combination of both drugs almost completely suppressed the growth of both cells in vitro (Figs. 5A and B) and in vivo (Figs. 5C and D). Figure 5A and B show that compared with intact RMG-1 cells, RMG-1HKD cells were more sensitive to PD98059 in vitro, indicating that the accelerated cell growth induced by HIF-1 inhibition could be reversed by drugs targeting other growth pathways, such as PD98059, and in the case of combination therapy, with drugs inducing HIF-1 inhibition, such as rapamycin. Figures 5C and D show that PD98059 more strongly suppressed tumor growth in RMG-1HKD cells than in RMG-1 cells. Furthermore, the combinatorial use of rapamycin and PD98059 completely suppressed tumor growth in both cell lines in vivo, showing that a combination of inhibitors against the PI3K or Ras pathways would be the most effective technique for suppressing OCCC.

---

**Table 1. Effect of cantharidin on the proliferation of RMG-1 cells in vitro**

| p value          | 24h | 48h | 72h |
|------------------|-----|-----|-----|
| RMG-1            |     |     |     |
| RMG-1; Cantharidin 0.1nM | n.s. | n.s. | n.s. |
| RMG-1; Cantharidin 1nM    | P < 0.05 | n.s. | n.s. |
| RMG-1; Cantharidin 10nM   | P < 0.05 | P < 0.05 | P < 0.05 |
| RMG-1HKD          | P < 0.01 | P < 0.01 | P < 0.01 |

Statistical analyses were performed using JMP software (SAS Institute Inc.). n.s., not significant.

---

**Figure 5. Effect of rapamycin, PD98059, and the combination of rapamycin with PD98059 on the growth of (A, C) RMG-1 and (B, D) RMG-1HKD (A, B) cells in vitro and (C, D) in vivo. (A, B) RMG-1 and RMG-1HKD cells were treated with 10 μM PD98059, 25 nM rapamycin, or both for the indicated periods. Cell proliferation was measured using the WST-8 assay. Injection of rapamycin or PD98059 suppressed the growth of both cell lines, although the growth of RMG-1HKD cells was significantly more sensitive to PD98059 than that of RMG-1 cells. The combination of the 2 drugs synergistically suppressed the growth of both cell lines. (C, D) The cells (density: 5 × 10⁶ cells in 100 μL PBS) were subcutaneously implanted into the backs of female Balb/c nu/nu mice (5 weeks of age). After 1 week, the tumor reached a certain size, as described in the “Materials and Methods” section, and the indicated concentrations of each drug were injected intraperitoneally twice a week for 4 weeks. The tumor volume was recorded once a week for a total of 5 weeks.**
Here we identified a new mechanism for the crosstalk between the PI3K and Ras pathways, wherein MEK is activated by the downregulation of HIF-1, a downstream target of mTOR, via PP2A inactivation. The scheme for this new mechanism is presented in Figure 7. In RMG-1 cells under normal conditions, upregulation of HIF-1 by mTOR activates PP2A, which in turn inactivates MEK. In RMG-1HKD cells under normal conditions, PP2A is not activated, which induces cancer progression via upregulation of the Ras pathway. When RMG-1 cells are subjected to both rapamycin and PD98059, rapamycin downregulates HIF-1 expression, which in turn activates MEK via PP2A inactivation, whereas PD98059 downregulates MEK activity, leading to the suppression of cancer progression. We revealed this regulation in the OCCC cell line, RMG-1. Although every cell or tissue type may have its own system by which the signaling pathways regulate each other, the crosstalk between the pathways by HIF-1 via PP2A may be ubiquitous. The crosstalk could be applied in the chemotherapy of cancers in which the PI3K pathway is activated, such as OCCC. The combination therapy using inhibitors against the Ras pathway, including MEK inhibitors, could augment the efficiency of mTOR inhibitors and help circumvent unfavorable adverse events in patients with cancers that involve activation of the PI3K pathway.

**Materials and Methods**

**Reagents**

The inhibitors rapamycin and PD98069 were purchased from Calbiochem (La Jolla, CA). Cantharidin was procured from Wako Pure Chemical Industries (Osaka, Japan). Unless otherwise stated, all reagents were obtained from Sigma-Aldrich (St. Louis, MO), Wako Pure Chemical Industries (Osaka, Japan), or Nacalai Tesque (Kyoto, Japan).

**Table 2. Effect of rapamycin, PD98059, and their combination on the proliferation of RMG-1 cells in vitro**

| p value | 24 h | 48 h | 72 h |
|---------|------|------|------|
| RMG-1   |      |      |      |
| RMG-1; PD98059 | * < 0.01 | n.s. | * < 0.01 |
| RMG-1; Rapamycin | * < 0.01 | * < 0.01 | * < 0.01 |
| RMG-1; Combination | * < 0.01 | * < 0.01 | * < 0.01 |

Statistical analyses were performed using JMP software (SAS Institute Inc.). n.s., not significant.

**Figure 6.** Effect of rapamycin, PD98059, or the combination of rapamycin with PD98059 on the tumor weight derived from RMG-1 and RMG-1HKD cells in vivo. The cancer cells were subcutaneously implanted into Balb/c nu/nu mice. At 4 weeks after drug injection, the mice were sacrificed and the tumors were surgically removed and weighed. (A) Alignment of the tumors removed from Balb/c nu/nu mice treated with vehicle (upper panel), rapamycin (middle upper panel), PD98059 (middle lower panel), and the drug combination (lower panel). (Right panels: RMG-1 cells, left panels: RMG-1HKD cells). The weights of (B) RMG-1- and (C) RMG-1HKD-derived tumors at 4 weeks after drug injection were measured and analyzed statistically (n = 2/vehicle, rapamycin, and PD98059; n = 3/drug combination).
To silence HIF-1α in RMG-1 cells, we used a retrovirus expression system involving a pSIREN-retroQ vector (Takara-bio, Shiga, Japan). Annealed oligonucleotides targeting human HIF-1α were ligated into a pSIREN-retroQ vector. The resulting vector was designated as pSIREN/HIF-1α. The oligonucleotide sequences were 5'-GATCCCAAAATACATGGGATTAACTGTGTGCTGTCCAGTTAATCCCATTGTATTTTTCTCGAG-3' and 5'-AATTCTCGAGAAAAAACAATACATGGGATTAACTGGACAGCACACAGTTAATCCCATATTGTG-3'.

**Retrovirus preparation**

Retrovirus particles were prepared using the retrovirus packaging kit Ampho (Takara-bio, Shiga, Japan) following the manufacturer’s instructions. In brief, pSIREN/HIF-1α was transfected into 293T cells in conjunction with vectors harboring the gag/pol and env genes, which code for the major viral structural proteins, using a calcium phosphate method. The conditioned medium was collected 48 h after transfection, filtered, and preserved in a deep freezer until infection.

**Establishment of RMG-1HKD cells**

RMG-1 cells were infected with the retrovirus particles. The cells were grown in selective media containing 1 μg/mL puromycin for 10 d HIF-1α expression of the surviving colonies was assessed by real-time polymerase chain reaction (PCR). RMG-1 cells that showed the greatest suppression of HIF-1α expression were named RMG-1HKD cells and used in subsequent experiments.

**Measurement of PP2A activity in RMG-1 and RMG-1HKD cells**

PP2A activities in RMG-1 and RMG-1HKD cells were measured using a PP2A immunoprecipitation phosphatase assay kit (Millipore, Billerica, MA) following the manufacturer’s instructions. In brief, cell lysates from each cell line were prepared in 20 mM imidazole-HCl (pH 7.0) with 2 mM EDTA, 2 mM EGTA, and 0.5% NP-40. The lysates were co-immunoprecipitated with an anti-PP2A catalytic subunit Ab (Millipore, Billerica, MA). The precipitates were mixed with the diluted substrate solution. PP2A activities were measured with an immunoradial immunoassay (NJ2001, Nalgene-Nunc, Rochester, NY) at a wavelength of 650 nm.

**Cell growth assays**

**WST-8 assay**

Cell growth was measured calorimetrically with a cell counting kit-8 (Wako Pure Chemical Industries, Osaka, Japan).
Colony formation assay

The colony formation assay was performed using a 6-well plate. First, the bottom layer was prepared using 2.5 mL of 0.5% low-melting agarose (Agarose SFR, AMRESCO LLC, Solon, OH) dissolved in a growth medium described earlier. Cells were prepared at a density of $1 \times 10^5$ cells/mL. Approximately 50 μL of the cell suspension and 1.4 mL of the 0.3% low-melting agarose in the growth medium were overlaid on the bottom of each well. To prevent moisture loss, another 0.5–1 mL of the growth media was overlaid. After 4 weeks, colonies were stained with 0.05% crystal violet, counted, and then imaged.

In vivo assay of RMG-1 and RMG-1HKD cells

Implantation of cancer cells into Balb/c nu/nu mice

RMG-1 or RMG-1HKD cells at a density of $5 \times 10^6$ cells in 100 μL of phosphate-buffered saline (PBS) were subcutaneously grafted into the bilateral flanks of 9 Balb/c nu/nu mice (5 weeks old).

Administration of inhibitors

After 1 week, when the tumors reached a volume of approximately 50 mm$^3$, the mice were randomized into 4 groups: vehicle control (PBS), rapamycin alone (2.5 mg/kg/day, twice a week intraperitoneally), PD98059 alone (0.25 mg/kg/day, twice a week intraperitoneally), and a combination of rapamycin with PD98059 (n = 2/vehicle, rapamycin, and PD98059; n = 3/drug combination). Tumor volumes were measured once a week and calculated using the following formula: $V = \pi \times (\text{length} \times \text{width})^2/6$. After 4 weeks, the mice were sacrificed under anesthesia and the tumors were excised, weighed, and then fixed with 4% paraformaldehyde in PBS for histological analyses.

Real-time reverse transcription (RT)-PCR

Real-time PCR analyses were performed as described previously. In brief, RMG-1 and RMG-1RR cells were plated onto a 6-well plate containing growth medium, incubated overnight, and then treated with 100 nM of rapamycin for 24 h. RMG-1HKD cells were also plated on a 6-well plate along with a control cell line, RMG-1. RNA from these cells was extracted using RNAzol RT (Molecular Research Inc., Cincinnati, OH) following the manufacturer’s instructions. cDNAs were synthesized using a Primerscript RT reagent kit (Takara-bio, Shiga, Japan) and subjected to real-time PCR analyses of HIF-1α and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using a Thermal cycler Dice Real-Time PCR System TP870 (Takara-bio, Shiga, Japan). The data was calculated using the ΔΔCt (threshold cycle) method. Expression of GAPDH was used for normalization.

Primers used in the amplification of genes assessed in the present study:

- HIF-1α:
  Forward: 5’-GAAAGCGCAAGTCCTCAAAG-3’
  Reverse: 5’-TGGGTAGGAGATGGAGATGC-3’

- GAPDH:
  Forward: 5’-ATTGCCCTCAACGACCACTT-3’
  Reverse: 5’-AGGTCCACCACCCTGTTGCT-3’

Western blot analysis

Preparation of cell lysate

Cells were lysed with a lysis buffer (1% Triton X-100, 0.25% deoxycholic acid, 0.1 M NaCl, pH 7.4) containing a protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). The protein concentration of the lysates was determined using a BCA protein assay kit (Pierce, Rockford, IL). To measure HIF-1α expression in the ovarian cancer cell lines, the cells were placed in a hypoxic chamber (BACTRON, SEL LAB, Portland, OR) under conditions of 2% O2, 5% CO2, and 37°C for 6 h prior to cell lysis.

SDS-PAGE and Western blot analysis

The proteins were subjected to SDS-PAGE, and the separated proteins were transferred onto a PVDF membrane.
References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013: CA Cancer J Clin 2013; 63:11-30; PMID:2335087

2. Matsuzuka N, Mandai M, Okamoto T, Yamaguchi K, Yamamura S, Oura T, Baba T, Hamashita J, Kang HS, Matsui S, et al. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci 2010; 101:2658-63; PMID:20140234; http://dx.doi.org/10.1111/j.1349-7006.2010.01736.x

3. De Luca CC, Liu M, Chiang GC, Dintermann NM, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/akt signaling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012; 16:Suppl 2:S17-27; PMID:22443084; http://dx.doi.org/10.1517/14728222.2011.639561

4. Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujita S, Yamashita Y, Kanemura M, Uda M, Sugita M, et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 2011; 11:50-57; PMID:21057220; http://dx.doi.org/10.4161/cbt.11.1.13413

5. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth activation to cancer, diabetes and ageing. Nat Rev Cancer 2008; 8:293-303; PMID:18793368; http://dx.doi.org/10.1038/nrc2461

6. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. The RAS-ERK targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Expert Opin Investig Drugs 2008; 17:849-58; PMID:18794129; http://dx.doi.org/10.1517/14728222.2011.639561

7. Menon MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36:320-8; PMID:21531565; http://dx.doi.org/10.1016/j.tibs.2011.03.006

8. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Ega A, Sasaki AT, Thomas G, Kouzma SC, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-74; PMID:18725988

9. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:1110-5; PMID:15728109; http://dx.doi.org/10.1093/annonc/mdi113

10. Mabuchi S, Kawasaki C, Atomoro DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Stanzo AJ, Schilder RJ, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009; 15:5404-13; PMID:19609197; http://dx.doi.org/10.1158/1078-0432.CCR-09-0365

11. Fujisawa Y, Nakagawa T, Takahara K, Inamoto T, Kiyama S, Anuma H, Asahi M. Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines. Oncol Lett 2013; 5:1765-70; PMID:23833638

12. Godwin AK, Meister A, D'Orsoglio PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in ovarian and breast cancer. Cancer Res 2004; 64:7678-83; PMID:15044608; http://dx.doi.org/10.1158/0008-5472.CAN-03-2971

13. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Ega A, Sasaki AT, Thomas G, Kouzma SC, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-74; PMID:18725988

14. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:1110-5; PMID:15728109; http://dx.doi.org/10.1093/annonc/mdi113

15. Mabuchi S, Kawasaki C, Atomoro DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Stanzo AJ, Schilder RJ, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009; 15:5404-13; PMID:19609197; http://dx.doi.org/10.1158/1078-0432.CCR-09-0365

16. Fujisawa Y, Nakagawa T, Takahara K, Inamoto T, Kiyama S, Anuma H, Asahi M. Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines. Oncol Lett 2013; 5:1765-70; PMID:23833638

17. Godwin AK, Meister A, D’Orsoglio PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in ovarian and breast cancer. Cancer Res 2004; 64:7678-83; PMID:15044608; http://dx.doi.org/10.1158/0008-5472.CAN-03-2971

18. Bae D, Ceryk S. Raf-independent, PP2A-dependent MEK activation in response to ERK silencing. Biochim Biophys Acta 2009; 1795:523-7; PMID:19465001; http://dx.doi.org/10.1016/j.bbrc.2009.07.014

19. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13133030; http://dx.doi.org/10.1038/nrc10817

20. Jakobik P, Mole DR, Tian YM, Wilson MJ, Gebert I, Goudey SJ, von Kalle C, Haebel HE, Mukherji M, Schofield CJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylase. Science 2001; 292:468-72; PMID:11455796; http://dx.doi.org/10.1126/science.1059796

21. Banks RE, Tirukonda P, Taylor C, Horningdall N, Asturi D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, et al. Genetic and epigenetic variants of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006; 66:2000-11; PMID:16484999; http://dx.doi.org/10.1158/0008-5472.CAN-05-3074

22. Tsuveroh T, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekitani T, Fujisaki A, Kawai K, Kanemura M, Yamashita Y, et al. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer Biol Ther 2010; 11:1357-66; PMID:20935474; http://dx.doi.org/10.4161/cbt.11.10.13843

23. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Biol Ther 2008; 8:6749-58; PMID:18794129; http://dx.doi.org/10.1517/14728222.2011.639561

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Funding
This work was supported by Grants-in-aid from the Japanese Ministry of Education, Culture, Sports, Science, and Technology [24390384 and 25670709 to M.O. and 22590297 to M.A.].

www.taylorandfrancis.com
Cancer Biology & Therapy
335